As filed · Fortis Healthcare Limited has informed the Exchange regarding material litigation filed by Northern TK Venture Pte Ltd., the Promoter shareholder of the Company ( NTK ), against Daiichi Sankyo Company
Fortis Healthcare Limited has informed the Exchange regarding material litigation filed by Northern TK Venture Pte Ltd., the Promoter shareholder of the Company ( NTK ), against Daiichi Sankyo Company, Limited before the Tokyo District Court in Japan. FORTIS HEALTHCARE LIMITED. November 7, 2024 and February 6, 2025 regarding a material litigation filed by Northern TK.
Litigation creates a contingent liability that is not in reported profit until it crystallises.
Prior statements by this company that CapitSignal has recorded changing.
We recorded a gross addition of 7 labs -- 7 new labs and 200-plus new customer touchpoints during this quarter, reflecting our continued focus on strengthening presence and accessibility across geographies.
We launched 19 new tests this quarter, expanding our capabilities in oncology, infectious diseases and autoimmune diagnostics.
The specialized portfolio contribution increased to 35% from 34% over the same period.
We continue to see a favorable shift in our portfolio mix with the contribution from preventive portfolio increasing to 14% in Q1 FY '27 from 12% in Q1 FY '26.
So we had originally planned it for the operationalization by the third quarter, end of third quarter.
Now we expect to commission it by March end.
